Voya Investment Management LLC Has $503,000 Position in Alphatec Holdings, Inc. $ATEC

Key Points

• Voya Investment Management LLC increased its stake in Alphatec Holdings, Inc. by 60.1% during the first quarter, bringing its holdings to a total value of $503,000.
• Alphatec's quarterly earnings data showed a 27.5% revenue increase year-over-year, with a reported EPS of $0.02, beating analysts' estimates.
• Equities analysts generally maintain a "buy" rating for Alphatec, with an average price target of $18.50 from six investment analysts.

Voya Investment Management LLC grew its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 60.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 49,561 shares of the medical technology company's stock after purchasing an additional 18,605 shares during the quarter. Voya Investment Management LLC's holdings in Alphatec were worth $503,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in Alphatec by 38,433.3% in the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after purchasing an additional 2,306 shares in the last quarter. Larson Financial Group LLC acquired a new position in Alphatec in the first quarter worth $54,000. Segment Wealth Management LLC acquired a new position in Alphatec in the first quarter worth $101,000. FORA Capital LLC acquired a new position in Alphatec in the first quarter worth $102,000. Finally, Pallas Capital Advisors LLC acquired a new position in Alphatec in the first quarter worth $105,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a research note on Monday, June 16th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Barclays reaffirmed an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Finally, Wall Street Zen lowered Alphatec from a "buy" rating to a "hold" rating in a research note on Friday. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $18.50.

Alphatec Trading Down 2.4%

NASDAQ ATEC opened at $15.02 on Friday. The stock has a 50-day simple moving average of $14.69 and a 200 day simple moving average of $12.36. The company has a market capitalization of $2.22 billion, a PE ratio of -13.29 and a beta of 1.02. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $16.70.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. The business had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm's revenue was up 27.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. Research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Craig E. Hunsaker sold 10,876 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $15.33, for a total value of $166,729.08. Following the completion of the sale, the executive vice president owned 1,389,142 shares in the company, valued at approximately $21,295,546.86. This represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Patrick Miles sold 300,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $15.73, for a total value of $4,719,000.00. Following the completion of the sale, the chief executive officer owned 5,564,078 shares of the company's stock, valued at $87,522,946.94. This represents a 5.12% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 686,057 shares of company stock valued at $10,439,311 in the last ninety days. 20.90% of the stock is currently owned by insiders.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.